[1]
|
Zane, L.T., Chanda, S., Jarnagin, K., et al. (2016) Crisaborole and Its Potential Role in Treating Atopic Dermatitis: Over-view of Early Clinical Studies. Immunotherapy, 8, 853-866. https://doi.org/10.2217/imt-2016-0023
|
[2]
|
Hanifin, J.M., Chan, S.C., Cheng, J.B., et al. (1996) Type 4 Phosphodiesterase Inhibitors Have Clinical and in Vitro An-ti-Inflammatory Effects in Atopic Dermatitis. Journal of Investigative Dermatology, 107, 51-56.
https://doi.org/10.1111/1523-1747.ep12297888
|
[3]
|
Nutten, S. (2015) Atopic Dermatitis: Global Epidemiology and Risk Factors. Annals of Nutrition and Metabolism, 66, 8-16. https://doi.org/10.1159/000370220
|
[4]
|
Cheape, A.C. and Murrell, D.F. (2017) 2% Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermati-tis. Expert Review of Clinical Immunology, 13, 415-423. https://doi.org/10.1080/1744666X.2017.1304820
|
[5]
|
Guttman-Yassky, E., Hanifin, J.M., Boguniewicz, M., et al. (2019) The Role of Phosphodiesterase 4 in the Pathophysiology of Atopic Dermatitis and the Perspective for Its Inhibi-tion. Experimental Dermatology, 28, 3-10.
https://doi.org/10.1111/exd.13808
|
[6]
|
Li, H., Zuo, J. and Tang, W. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology, 9, Article No. 1048. https://doi.org/10.3389/fphar.2018.01048
|
[7]
|
Zane, L.T., Hughes, M.H. and Shakib, S. (2016) Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers. American Journal of Clinical Dermatology, 17, 519-526. https://doi.org/10.1007/s40257-016-0204-6
|
[8]
|
Zane, L.T., Kircik, L., Call, R., et al. (2016) Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. Pediatric Dermatology, 33, 380- 387. https://doi.org/10.1111/pde.12872
|
[9]
|
Stein Gold, L.F., Spelman, L., Spellman, M.C., et al. (2015) A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents with Mild to Moderate Atopic Dermatitis. Journal of Drugs in Dermatology, 14, 1394-1399.
|
[10]
|
Eichenfield, L.F., Call, R.S., Forsha, D.W., et al. (2017) Long-Term Safety of Crisaborole Ointment 2% in Children and Adults with Mild to Moderate Atopic Dermatitis. Journal of the American Academy of Dermatology, 77, 641- 649.E5. https://doi.org/10.1016/j.jaad.2017.06.010
|
[11]
|
Schlessinger, J., Shepard, J.S., Gower, R., et al. (2020) Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to <24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology, 21, 275-284. https://doi.org/10.1007/s40257-020-00510-6
|
[12]
|
林杨杨, 廉佳, 宫泽琨, 卞亚伟, 刘欣欣, 毕田田, 王莹, 冯小燕, 李钦峰. 克立硼罗软膏治疗儿童轻中度特应性皮炎65例疗效观察[J]. 中国实用儿科杂志, 2021, 36(9): 693-696.
|
[13]
|
Choudhary, S., Pradhan, D., Khan, N.S., et al. (2020) De-coding Psoriasis: Integrated Bioinformatics Approach to Understand Hub Genes and Involved Pathways. Current Pharmaceutical Design, 26, 3619-3630.
https://doi.org/10.2174/1381612826666200311130133
|
[14]
|
Cannavò, S.P., Riso, G., Casciaro, M., et al. (2019) Oxidative Stress Involvement in Psoriasis: A Systematic Review. Free Radical Research, 53, 829-840. https://doi.org/10.1080/10715762.2019.1648800
|
[15]
|
Orlik, C., Deibel, D., Küblbeck, J., et al. (2020) Keratino-cytes Costimulate Naive Human T Cells via CD2: A Potential Target to Prevent the Development of Proinflammatory Th1 Cells in the Skin. Cellular & Molecular Immunology, 17, 380-394. https://doi.org/10.1038/s41423-019-0261-x
|
[16]
|
Hashim, P.W., Chima, M., Kim, H.J., et al. (2020) Crisaborole 2% Ointment for the Treatment of Intertriginous, Anogenital, and Facial Psoriasis: A Double-Blind, Randomized, Vehi-cle-Controlled Trial. Journal of the American Academy of Dermatology, 82, 360-365. https://doi.org/10.1016/j.jaad.2019.06.1288
|
[17]
|
Liu, Y.Y. and Li, W. (2022) Successful Treatment with Crisabo-role for Facial Lesions Refractory to Adalimumab in a Man with Psoriasis: A Case Report. Dermatologic Therapy, 35, e15424. https://doi.org/10.1111/dth.15424
|
[18]
|
Nagui, N., Gaballah, B., Rashed, L. and Sany, I. (2021) Evaluation of Phosphodiesterase 4 Enzyme Levels in Lesional Skin and Serum of Vitiligo Patients. Journal of the Egyptian Wom-en’s Dermatologic Society, 18, 186-190.
https://doi.org/10.4103/jewd.jewd_20_21
|
[19]
|
Tam, I., Kahn, J.S. and Rosmarin, D. (2021) Repigmentation in a Patient with Vitiligo on Crisaborole 2% Ointment. JAAD Case Reports, 11, 99-101. https://doi.org/10.1016/j.jdcr.2021.03.028
|
[20]
|
Robbins, A.B., Gor, A. and Bui, M.R. (2018) Topical Crisaboro-le—A Potential Treatment for Recalcitrant Palmoplantar Psoriasis. JAMA Dermatology, 154, 1096-1097. https://doi.org/10.1001/jamadermatol.2018.2397
|
[21]
|
Wei, G., Rodriguez-Waitkus, P. and Soylu, L. (2021) A Rare Case of Lichen Simplex Chronicus in an Adolescent Female Successfully Managed with Crisaborole. Dermatologic Therapy, 34, e14752. https://doi.org/10.1111/dth.14752
|
[22]
|
Barney, E., Prose, N.S. and Ramirez, M. (2019) In-flammatory Linear Verrucous Epidermal Nevus Treated Successfully with Crisaborole Ointment in a 5-Year-Old Boy. Pediatric Dermatology, 36, 404-405.
https://doi.org/10.1111/pde.13793
|
[23]
|
Henning, C., Meyers, S., Swift, R., Eades, B., Bussell, L., Spektor, T.M. and Berenson, J.R. (2020) Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranu-loma Associated with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 20, E492-E495. https://doi.org/10.1016/j.clml.2020.03.016
|
[24]
|
Keren, A., Shemer, A., Ullmann, Y., et al. (2015) The PDE4 In-hibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin in Vivo. Journal of Dermato-logical Science, 77, 74-76.
https://doi.org/10.1016/j.jdermsci.2014.11.009
|
[25]
|
Taneja, N. and Gupta, S. (2020) Apremilast Is Efficacious in Refractory Alopecia Areata. Journal of Dermatological Treatment, 31, 727-729. https://doi.org/10.1080/09546634.2019.1616046
|
[26]
|
张帆, 糜自豪, 孙勇虎. 外用磷酸二酯酶4抑制剂软膏治疗斑秃一例附文献复习[J]. 中国麻风皮肤病杂志, 2022, 38(4): 217-219.
|